139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Dent, R.; Oliveira, M.; Isakoff, S. J.; Im, S.-A.; Espié, M.; Blau, S.; Tan, A. R.; Saura, C.; Wongchenko, M.; Xu, N.; Bradley, D.; Reilly, S.-J.; Mani, A.; Kim, S.-B.

Published in

Elsevier, Annals of Oncology, (31), p. S64-S65, 2020

DOI: 10.1016/j.annonc.2020.03.240

Tools

Export citation

Search in Google Scholar

139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Journal article published in 2020 by R. Dent, M. Oliveira, S. J. Isakoff, S.-A. Im, M. Espié, S. Blau, A. R. Tan, C. Saura, M. Wongchenko, N. Xu, D. Bradley, S.-J. Reilly, A. Mani, S.-B. Kim

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)